Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses
- PMID: 15203918
- DOI: 10.1080/10611860410001670026
Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses
Abstract
Dendritic cells (DCs) in the peripheral tissues act as sentinels of the immune system. They detect and capture pathogens entering the body and present their antigens to T cells to trigger responses directed towards elimination of the pathogen. The induction of peripheral tolerance against self and certain foreign antigens is also believed to be mediated through DCs. The outcome of any immune response is largely controlled by the microenvironment of antigen capture, processing and presentation by DCs. The "context" of antigen delivery to DCs will directly influence the microenvironment of antigen presentation and hence the regulation of immune responses. We report here preliminary investigations describing the formulation of a pharmaceutically acceptable, biodegradable, and strategic nanoparticulate delivery system, and its application for efficient antigen loading of DCs to achieve antigen specific T cell activation. "Pathogen-mimicking" nanoparticles capable of interacting with DCs were fabricated by incorporating monophosphoryl lipid A (MPLA; toll-like receptor (TLR) 4 ligand) or CpG ODN (seq #2006; TLR9 ligand) in biodegradable copolymer, poly(D,L,-lactic-co-glycolic acid) (PLGA). The uptake of PLGA nanoparticles by human umbilical cord blood derived DCs (DCs propagated from CD34 progenitors) was conclusively demonstrated by scanning electron microscopy (SEM), fluorescence activated cell sorting (FACS) and confocal laser scanning microscopy (CLSM). Cell phenotype at day 12 of cultures was determined as immature DC using specific cell surface markers, i.e. CD11c (approximately 90%), MHC-II (approximately 70%), CD86 (approximately 20%), CD83 (approximately 5%), CD80 (approximately 40%), CD40 (approximately 40%), and CCR7 (approximately 5%). Tetanus toxoid (TT), a model antigen, was encapsulated in nanoparticles along with an immunomodulator, i.e. either MPLA or CpG ODN. DCs pulsed with various antigen formulations were co-cultured with autologous naïve T cells at various cell ratios (DC: T cells were 1:5-20). The DCs pulsed with TT and MPLA together in nanoparticles induced significantly higher T cell proliferation (P<0.05) as compared to when DCs pulsed with TT and MPLA in solution were employed. A similar trend was observed when CpG ODN was used instead of MPLA in the TT nanoparticles. This strategy of antigen delivery to DCs was then tested with a cancer vaccine candidate, a MUC1 lipopeptide. The T cell proliferation observed in the presence of nanoparticulate MUC1 and MPLA pulsed-DCs was much higher than DCs pulsed with soluble antigen (P<0.0005). These results indicate that PLGA nanoparticles mimicking certain features of pathogens are efficient delivery systems for targeting vaccine antigens to DCs and activation of potent T cell responses.
Similar articles
-
"Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells.J Immunother. 2007 May-Jun;30(4):378-95. doi: 10.1097/CJI.0b013e31802cf3e3. J Immunother. 2007. PMID: 17457213
-
Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells.Vaccine. 2004 Jun 23;22(19):2406-12. doi: 10.1016/j.vaccine.2003.12.032. Vaccine. 2004. PMID: 15193402
-
Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.J Exp Clin Cancer Res. 2016 Oct 26;35(1):168. doi: 10.1186/s13046-016-0444-6. J Exp Clin Cancer Res. 2016. PMID: 27782834 Free PMC article.
-
Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.Adv Drug Deliv Rev. 2011 Sep 10;63(10-11):943-55. doi: 10.1016/j.addr.2011.05.021. Epub 2011 Jun 6. Adv Drug Deliv Rev. 2011. PMID: 21679733 Review.
-
Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.Adv Drug Deliv Rev. 2013 Oct;65(10):1386-99. doi: 10.1016/j.addr.2013.05.013. Epub 2013 Jun 7. Adv Drug Deliv Rev. 2013. PMID: 23751781 Review.
Cited by
-
Nanotechnology: intelligent design to treat complex disease.Pharm Res. 2006 Jul;23(7):1417-50. doi: 10.1007/s11095-006-0284-8. Epub 2006 Jun 21. Pharm Res. 2006. PMID: 16779701 Review.
-
Harnessing Dendritic Cells for Poly (D,L-lactide-co-glycolide) Microspheres (PLGA MS)-Mediated Anti-tumor Therapy.Front Immunol. 2019 Apr 5;10:707. doi: 10.3389/fimmu.2019.00707. eCollection 2019. Front Immunol. 2019. PMID: 31024545 Free PMC article. Review.
-
Cell membrane-derived nanomaterials for biomedical applications.Biomaterials. 2017 Jun;128:69-83. doi: 10.1016/j.biomaterials.2017.02.041. Epub 2017 Mar 1. Biomaterials. 2017. PMID: 28292726 Free PMC article. Review.
-
Prospects and applications of nanobiotechnology: a medical perspective.J Nanobiotechnology. 2012 Jul 20;10:31. doi: 10.1186/1477-3155-10-31. J Nanobiotechnology. 2012. Retraction in: J Nanobiotechnology. 2012 Oct 04;10:40. doi: 10.1186/1477-3155-10-40. PMID: 22817658 Free PMC article. Retracted. Review.
-
Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity.Front Oncol. 2012 Oct 10;2:136. doi: 10.3389/fonc.2012.00136. eCollection 2012. Front Oncol. 2012. PMID: 23087900 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous